KPI is working with scientists, doctors, and patients to develop our autoimmune pipeline. Leveraging state-of-the-art science to create novel medicines for serious illness, KPI is focused on high-quality candidates for diseases with high unmet patient need.
|Platform||Therapeutic Area||Indications||Discovery||Preclinical||Phase 1||Phase 2||Phase 3|
|Systemic||Myositis, Cutaneous Lupus, Psoriasis, Psoriatic Arthritis|
|Dermatology||Atopic Dermatitis, mild to moderate Psoriasis|
|Ophthalmology||Uveitis, Dry Eye Syndrome (DES), other autoimmune ocular diseases|
*This program is jointly developed by KPI Therapeutics and its sister corporation Kineta, Inc.